Abstract:CARM1 methylated R23 of PPP1CA, affected the dephosphorylation of AKT‐T450 and AMPK‐T172 CARM1 increased the activities of phosphofructokinase‐1 (PFK1) and pructose‐2,6‐biphosphatase3 (PFKFB3), causing an up‐regulation of glycolytic flux CARM1 regulates glucose metabolism CARM1 affects both osteogenesis and osteoclast differentiation. Background The imbalance between osteoblasts and osteoclasts may lead to osteoporosis. Osteoblasts and osteoclasts have different energy requirements, with aerobic glycolysis being the prominent metabolic feature of osteoblasts, while osteoclast differentiation and fusion are driven by oxidative phosphorylation. Methods By polymerase chain reaction as well as Western blotting, we assayed coactivator‐associated arginine methyltransferase 1 (CARM1) expression in bone tissue, the mouse precranial osteoblast cell line MC3T3‐E1 and the mouse monocyte macrophage leukaemia cell line RAW264.7, and expression of related genes during osteogenic differentiation and osteoclast differentiation. Using gene overexpression (lentivirus) and loss‐of‐function approach (CRISPR/Cas9‐mediated knockout) in vitro, we examined whether CARM1 regulates osteogenic differentiation and osteoblast differentiation by metabolic regulation. Transcriptomic assays and metabolomic assays were used to find the mechanism of action of CARM1. Furthermore, in vitro methylation assays were applied to clarify the arginine methylation site of PPP1CA by CARM1. Results We discovered that CARM1 reprogrammed glucose metabolism in osteoblasts and osteoclasts from oxidative phosphorylation to aerobic glycolysis, thereby promoting osteogenic differentiation and inhibiting osteoclastic differentiation. In vivo experiments revealed that CARM1 significantly decreased bone loss in osteoporosis model mice. Mechanistically, CARM1 methylated R23 of PPP1CA, affected the dephosphorylation of AKT‐T450 and AMPK‐T172, and increased the activities of phosphofructokinase‐1 and pructose‐2,6‐biphosphatase3, causing an up‐regulation of glycolytic flux. At the same time, as a transcriptional coactivator, CARM1 regulated the expression of pyruvate dehydrogenase kinase 3, which resulted in the inhibition of pyruvate dehydrogenase activity and inhibition of the tricarboxylic acid cycle, leading to a subsequent decrease in the flux of oxidative phosphorylation. Conclusions These findings reveal for the first time the mechanism by which CARM1 affects both osteogenesis and osteoclast differentiation through metabolic regulation, which may represent a new feasible treatment strategy for osteoporosis.

Biochemical Properties of CARM1: Impact on Western Blotting and Proteomic Studies

Virtual Screening with a Structure-Based Pharmacophore Model to Identify Small-Molecule Inhibitors of CARM1

The emerging role of CARM1 in cancer

CARM1/PRMT4: Making Its Mark beyond Its Function as a Transcriptional Coactivator

Biochemical Control of CARM1 Enzymatic Activity by Phosphorylation*

Development of Potent and Selective Coactivator-Associated Arginine Methyltransferase 1 (CARM1) Degraders

PGAM1 Regulation of ASS1 Contributes to the Progression of Breast Cancer Through the Camp/ampk/cebpb Pathway

Research Progress on CARM1 and its Relationship with Colorectal Cancer

CARM1 hypermethylates the NuRD chromatin remodeling complex to promote cell cycle gene expression and breast cancer development

Small-Molecule Modulators Targeting Coactivator-Associated Arginine Methyltransferase 1 (CARM1) as Therapeutic Agents for Cancer Treatment: Current Medicinal Chemistry Insights and Emerging Opportunities

Identification, Synthesis, and Biological Evaluations of Potent Inhibitors Targeting Type I Protein Arginine Methyltransferases

A Chemical Probe of CARM1 Alters Epigenetic Plasticity Against Breast Cancer Cell Invasion

A CARM1 Inhibitor Potently Suppresses Breast Cancer Both In Vitro and In Vivo

Structural and biochemical evaluation of bisubstrate inhibitors of protein arginine N-methyltransferases PRMT1 and CARM1 (PRMT4)

Tyrosine phosphorylation of CARM1 promotes its enzymatic activity and alters its target specificity

Arginine methylation of PPP1CA by CARM1 regulates glucose metabolism and affects osteogenic differentiation and osteoclastic differentiation

USP4/CARM1 Axis Promotes the Malignant Transformation of Breast Cancer Cells by Upregulating SLC7A11 Expression

Structure-Based Discovery of Potent CARM1 Inhibitors for Solid Tumor and Cancer Immunology Therapy

Epigenetic Regulation of Cardiomyocyte Maturation by Arginine Methyltransferase CARM1

Loss of CARM1 Results in Hypomethylation of Thymocyte Cyclic AMP-regulated Phosphoprotein and Deregulated Early T Cell Development

Impact of short-term, pharmacological CARM1 inhibition on skeletal muscle mass, function, and atrophy in mice